Task force hears presentation on comprehensive obesity care, pilot shows adherence and cost savings

Dr. Saunders, an obesity medicine physician affiliated with Weill Cornell Medicine, told the Joint Interim Committees’ task force that obesity should be treated as a chronic disease and that effective, long‑term management requires personalized care, monitoring and multidisciplinary support.

She cited national prevalence and economic estimates, saying obesity contributes to a sizable portion of health care spending and referencing an Aon analysis that she said put the annual U.S. cost as high as $1.7 trillion. "The landscape has just absolutely been transformed," she said, adding that GLP‑1 receptor agonists have been linked with "44 percent lower risk of hospitalizations and major cardiovascular events" in some studies when used as part of comprehensive care.

To illustrate implementation, Dr. Saunders described a 2023 pilot in Connecticut run through a closed provider network. She said an independent actuarial review by Milliman looked at roughly 4,000 participants and found about $3,000,000 in annualized cost savings or cost avoidance; the program reported an adherence rate of 86 percent. "We were able to achieve over 3,000,000, on an annualized basis in terms of, you know, cost savings, cost avoidance," she said. Dr. Saunders attributed the results to careful patient selection, acuity‑based prescribing, training and wraparound behavioral and monitoring supports.

She warned that without those supports, the majority of patients who start GLP‑1 therapy stop within a year, often regaining weight and losing clinical benefit. Dr. Saunders said two‑year internal data (not yet public) show about 14 percent average weight loss with non‑GLP regimens and nearly 20 percent when GLP‑1 medications are combined with other therapies; she also cited Weill Cornell publications reporting roughly 16 percent weight loss sustained over time for many patients.

During a question‑and‑answer period, she emphasized individualized titration and ongoing monitoring to maintain benefits: "This is a chronic disease, so just like hypertension... you get to the regimen you need, and then you keep somebody on that regimen." The task force and presenters discussed a recent CMS announcement that could enable broader Medicaid engagement with manufacturers and lead to lower prices; Dr. Saunders noted CMS projections of cost neutrality after two years but said coverage details such as copay levels remain uncertain.

The presenter urged the task force to consider coverage policies that prioritize evidence‑based, multidisciplinary programs and the training of clinicians to ensure sustainable, high‑quality care. The meeting adjourned without formal votes on coverage changes.

Next steps: the task force has no recorded motion from this session; members indicated interest in further discussion of program design, prior‑authorization criteria and workforce training.